A nurse is reviewing the BUN result of a client who is taking cyclosporine following a kidney transplant. Which of the following laboratory studies should the nurse recognize as another renal function study that should be monitored?

Choice A reason: A quiet environment reduces sensory stimulation, which can elevate intracranial pressure (ICP) by increasing cerebral blood flow. Minimizing noise helps stabilize intracranial dynamics, preventing exacerbation of brain injury. This intervention supports neurological stability, critical in traumatic brain injury management to avoid secondary damage.
Choice B reason: Monitoring vital signs every 8 hours is inadequate for increased ICP, which requires frequent checks (e.g., every 1-2 hours). Changes in blood pressure or respiration signal worsening ICP, risking herniation. Infrequent monitoring delays detection of neurological deterioration, compromising timely intervention in brain injury.
Choice C reason: Coughing and deep breathing increase intrathoracic pressure, elevating ICP by impeding cerebral venous return. This is contraindicated in traumatic brain injury, as it risks worsening cerebral edema or causing herniation, potentially leading to severe neurological damage or fatal outcomes in affected clients.
Choice D reason: A 30-degree head-of-bed elevation promotes cerebral venous drainage, reducing ICP. This position optimizes cerebral perfusion pressure, minimizing venous congestion in traumatic brain injury. It is a critical intervention to prevent secondary brain injury, supporting neurological recovery by stabilizing intracranial dynamics effectively.
Choice E reason: Stool softeners prevent straining during bowel movements, which increases intrathoracic and intracranial pressure. In traumatic brain injury, straining risks exacerbating ICP, potentially causing herniation. This intervention ensures smoother bowel movements, maintaining ICP stability and supporting safe management of brain injury.

Choice A reason: Disulfiram is an oral medication, not injectable, used to deter alcohol consumption by causing adverse reactions. Monthly injections apply to drugs like naltrexone, not disulfiram, which requires daily oral dosing to maintain its deterrent effect in alcohol use disorder treatment.
Choice B reason: Taking disulfiram before quitting alcohol is incorrect, as it is started post-abstinence to prevent relapse. Disulfiram inhibits aldehyde dehydrogenase, causing acetaldehyde buildup if alcohol is consumed, making it effective only in alcohol-free clients to deter drinking.
Choice C reason: Avoiding over-the-counter medications with alcohol is correct, as disulfiram causes severe reactions (nausea, flushing) with alcohol ingestion, including from medications like cough syrups. This reflects understanding of disulfiram’s mechanism, ensuring safety by preventing unintended alcohol exposure.
Choice D reason: Continuing disulfiram for 5 years is not standard, as duration varies per treatment plan. Disulfiram supports early abstinence, not fixed long-term use. This statement misrepresents its role, as therapy length depends on individual recovery needs, not a predetermined timeframe.